BNTX - FDA places partial hold on study for MediLink BioNTech cancer drug
2024-06-17 11:17:09 ET
More on BioNTech
- BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical
- BioNTech SE 2024 Q1 - Results - Earnings Call Presentation
- BioNTech SE (BNTX) Q1 2024 Earnings Call Transcript
- FDA recommends KP.2 strain be used in updated COVID-19 shots
- FDA selects JN.1 variant for next COVID vaccine campaign